Evidence map›Paper›PMID 27598831›Full record

SynthesisScandinavian journal of gastroenterology2016

Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area: a meta-analysis of random controlled trials.

Tengfei Si, Yongjun Chen, Di Ma, Xiaoyong Gong, Kui Yang, Ruoyu Guan, Chenghong Peng

Open access · hybridAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scandinavian journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Regional Ischemic Preconditioning Has Clinical Value in Cirrhotic HCC Through MAPK Pathways.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2019
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Tengfei Sia Department of General Surgery , Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China.
Yongjun Chena Department of General Surgery , Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China.
Di Maa Department of General Surgery , Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China.
Xiaoyong Gonga Department of General Surgery , Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China.
Kui Yanga Department of General Surgery , Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China.
Ruoyu Guana Department of General Surgery , Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China.
Chenghong Penga Department of General Surgery , Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China.
Ruijin Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe aimed to systematically evaluate the influence of preoperative transarterial chemoembolization (TACE) for resectable hepatocellular carcinoma (HCC) on long-term prognosis and perioperative safety. MATERIALS AND

methodsDatabases including PubMed, Embase, Cochrane, Wanfang, CNKI, VIP data were searched, combined with Manual Retrieval and Cited Reference Search to collect the published randomized controlled trial (RCT) about the influence of pre-TACE for curative resection of HCC. The searching cutoff date was 2016/02/25, all the data obtained were statistically analyzed using RevMan5.2 software recommended by Cochrane Collaboration.

resultsA total of 5 RCT including 430 (pre-TACE group: 212, surgery alone group: 218) patients were included. The results of meta-analysis showed that: there was no difference between the 2 groups on overall survival (OS) rate [HR 1.25, 95%CI (0.92-1.68)], disease free survival (DFS) rate [HR 0.95 (0.76-1.19)], perioperative mortality rate [OR 0.70 (0.22-2.30)], or blood loss [SMD 0.07 (-0.14-0.29)], whereas the subgroup analysis revealed that pre-TACE would result in longer operation time [SMD 0.31 (0.06-0.57)], higher postoperative morbidity rate [OR 1.90 (1.02-3.53)] and combined resection rate of perihepatic organs [OR 5.46 (2.73-11.78)] in subgroup with mean tumor diameter >5cm.

conclusionsAccording to our study, pre-TACE treatment cannot improve the long-term prognosis of resectable HCC. With the growth of the tumor diameter, especially when it is over 5cm, it might add difficulties to surgery and affect the perioperative safety.

Indexed as

AsiaBlood Loss, SurgicalCarcinoma, HepatocellularChemoembolization, TherapeuticDisease-Free SurvivalHepatectomyHumansLiver NeoplasmsOperative TimePostoperative ComplicationsRandomized Controlled Trials as TopicSurvival RateTreatment OutcomeHepatocellularmeta-analysisresectabletransarterial

Identifiers

PMID27598831
PMCPMC5152561
OpenAlexW2493364304

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.